1.Diagnostic agreement between two diagnosticians in a community study of dementia.
Journal of Korean Neuropsychiatric Association 1993;32(5):818-825
No abstract available.
Dementia*
2.Clinical Management for Geriatric Dementia.
Journal of the Korean Academy of Family Medicine 1997;18(12):1406-1416
No abstract available.
Dementia*
3.cognitive functions in questionable dementia and non-dementia.
Journal of Korean Neuropsychiatric Association 1992;31(6):1092-1099
No abstract available.
Dementia*
4.cognitive functions in questionable dementia and non-dementia.
Journal of Korean Neuropsychiatric Association 1992;31(6):1092-1099
No abstract available.
Dementia*
5.Dementia in Psychiatry.
Journal of the Korean Neurological Association 1985;3(1):25-27
No abstract available.
Dementia*
6.Dementia in Neruology.
Journal of the Korean Neurological Association 1985;3(1):17-24
No abstract available.
Dementia*
7.A Korean Model of Dementia Management.
Journal of Korean Geriatric Psychiatry 2006;10(1):10-13
No abstract available.
Dementia*
8.Dementia .
Journal of the Korean Medical Association 1997;40(10):1319-1328
No abstract available.
Dementia*
9.Cause, evaluation and treatment of dementia: for primar care physician.
Journal of the Korean Academy of Family Medicine 2001;22(5):619-630
No abstract available.
Dementia*
10.Relationship between serum high-sensitivity C-reactive protein levels and cognitive function in patients with Parkinson’s disease
Seong-Min Choi ; Byeong C Kim ; Kyung Wook Kang ; Kang- Ho Choi ; Tai-Seung Nam ; Joon-Tae Kim ; Seung-Han Lee ; Man-Seok Park ; Myeong-Kyu Kim ; Ki-Hyun Cho
Neurology Asia 2016;21(4):349-356
Inflammation might be associated with cognitive impairment and be involved in the pathogenesis of
Parkinson’s disease (PD). High-sensitivity C-reactive protein (hs-CRP) is a sensitive biomarker of
systemic inflammation. This study aimed to investigate whether serum concentrations of hs-CRP are
related to cognitive function in patients with PD. Patients with PD (n = 113, Hoehn and Yahr [H-Y] stage
1-4) underwent evaluation of serum hs-CRP and comprehensive neuropsychological tests that covered
the cognitive domains of attention, language, visuospatial function, memory, and executive functions.
We categorized subjects with PD as having normal cognition (n=48), mild cognitive impairment (MCI)
(n=41), or dementia (n=24). Patients with dementia had a higher hs-CRP level than patients with MCI
or normal cognition (2.76 ± 2.53 vs. 1.27 ± 1.99 vs. 0.73 ± 0.88 mg/L, P=0.001). Serum hs-CRP
levels were inversely associated with the Mini-Mental State Examination scores and performance on
neuropsychological tests of language, visuospatial function, visual memory, and executive function.
After controlling for age, sex, symptom duration, education, H-Y stage, and Unified Parkinson’s Disease
Rating Scale motor score, multiple regression analyses indicated statistically significant associations
between hs-CRP levels and performance on neuropsychological tests of visuospatial function, visual
memory, and executive function. This study suggests a possible relationship between serum hs-CRP
levels and cognitive function in patients with PD, with higher levels of hs-CRP being associated with
poor performance on tests of visuospatial function, visual memory, and executive function.
Dementia